Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin + pembrolizumab versus gemcitabine + platinum as first-line treatment for advanced urothelial cancer
NL-OMON60364Phase 3Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Seagen Inc. Primary endpoints: Progression-free survival and Overall survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON60364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60364.